All In MedTech

Device Trial Radar · NCT03716505

Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines

A Randomized, Multicenter, Double-blind, Parallel, Sham-controlled Study of Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines. (Premium II)

Last checked: Nov 20, 2026Latest source record: Sep 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 231 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

231

Actual

Start

Nov 2, 2018

Primary completion

Sep 9, 2020

Study completion Sep 9, 2020

Sponsor

Lead sponsor
ElectroCore INCNot on our public-company list
Sponsor type
Industry
First posted
Oct 23, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to investigate if the use of gammaCore Sapphire™ device reduces the number of migraines preventatively.

Conditions

  • Migraine Disorders

Interventions

  • gammaCore Sapphire activeDevice

    GammaCore Sapphire™ is a handheld, non-invasive, low voltage electrical device which stimulates the vagus nerve by producing weak 120 second electrical stimulation cycles that may help reduce, ease, lessen or stop your migraine symptoms. GammaCore Sapphire™ has been approved for the treatment of headache, including migraine by the United States Food and Drug Administration (FDA).

  • gammaCore Sapphire ShamDevice

    The sham device is a hand-held portable device that appears identical to gammaCore Sapphire, in look, weight, visual and audible feedback, user application, and control. Like gammaCore Sapphire, the sham device is a multi-use device.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and effectiveness of gammaCore Sapphire as a treatment for the prevention of a migraine during the double-blind period measured by Incidence of Unexpected Adverse Events.Time frame: 12 weeks

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Scottsdale, Arizona

  • The Research Center of Southern California

    Carlsbad, California

  • Stanford University Medical Center Hoover Pavilion

    Palo Alto, California

27 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.